Latest Operational Transformation News

PointsBet Holdings Limited has appointed Andrew Catterall as Group CEO effective February 2026, with founder Sam Swanell transitioning to an advisory role while remaining on the Board.

SomnoMed Limited reported a robust FY25 with revenue surpassing guidance and a landmark FDA clearance for its Rest Assure® oral device, setting the stage for sustained growth in oral appliance therapy.

AVADA Group’s CEO Donald Montgomery outlined a year of operational consolidation and transformation at the 2025 AGM, reporting significant safety improvements and early signs of revenue growth in 2026 despite ongoing market challenges.

Nine Entertainment reported a resilient FY25 with strategic transformation gains, digital subscription growth, and a major capital return following the sale of its Domain stake. Leadership changes and regulatory challenges frame its path forward.

MedAdvisor reports a sharp 53% drop in 1Q FY26 revenue driven by U.S. regulatory and sector challenges, while advancing a major platform transformation and selling its ANZ business to emerge debt-free.

Elixinol Wellness has raised $2.5 million through a well-supported placement and appointed industry veteran Gavin Evans as strategic advisor to drive its next phase of growth and operational reset.

AVADA Group Limited reported a significant net loss of $17.6 million for FY25, driven by major impairments in New Zealand and New South Wales operations amid challenging market conditions. The company completed a strategic consolidation of its Australian businesses and appointed new senior management to steer operational transformation.

Bapcor Limited reported a decline in FY25 pro-forma net profit after tax by 8.4%, alongside a successful $170 million debt refinancing extending maturities to 2029-2031. The company declared a fully franked final dividend and announced significant board and executive changes.

Doctor Care Anywhere has reported a profitable first half of 2025, driven by strong margin improvements and operational efficiencies. The telehealth provider’s strategic expansion and app enhancements signal promising growth ahead.

EML Payments reported a 9% revenue increase and 13% rise in underlying EBITDA for FY25, driven by strategic partnerships and operational transformation. The company sets a steady growth outlook for FY26 despite expected interest revenue headwinds.

Genetic Signatures reported a 63% revenue increase to $15.9 million in FY25, alongside a 28% reduction in underlying losses and a strategic shift in its automated diagnostics platform development.

Genetic Signatures Limited reported a 63% revenue surge to $15.9 million in FY25, driven by strong Australian sales and progress in EMEA, while navigating a $20.1 million net loss and a strategic pivot towards partnerships for automated diagnostics.